Recent studies have suggested that a rare class of p53 mutants found in tumours has a subtle transcriptional defect aecting bax induction but not p21 induction. We have therefore developed simple functional assays in yeast which can be used to identify these mutants. Analysis of 51 dierent mutations observed in human tumours showed that all mutants tested scored as mutant with the bax reporter strain but nine scored as wild-type with the p21 reporter strain. These results, which can be explained by the lower anity of the p53 protein for the bax site, may suggest that p21 is not the key target of p53 mutations in tumours. Since p21 status has recently been shown to modulate the chemotherapeutic and radiotherapeutic sensitivities of cancerous cells, the functional assays described here may have important clinical implications.
The p53 gene is exquisitely sensitive to mutation and p53 mutations represent the most frequently observed molecular alterations in human cancers. More than 90% of the mutations are located within the DNA binding domain between amino-acids 102 and 292 (Beroud et al., 1996; Hainaut et al., 1997) . This domain consists of a b sandwich that supports two large loops and a loop/sheet/helix structure which contact the DNA (Pavletich et al., 1993; Cho et al., 1994) . p53 binds DNA as a tetramer, and high anity p53 binding sites contain two copies of a 10 bp motif (5'-PuPuPuC(A/T)(T/A)GPyPyPy-3'), separated by 0 ± 13 bp, each decamer binding a primary p53 dimer (El-Deiry et al., 1992; Cho et al., 1994) . Most p53 mutations fall into one of two classes: those aecting DNA contact residues directly (K120, S241, R248, R273, A276, C277, R280 and R283), and those aecting the alignment of these residues relative to the DNA through modi®cation of the overall protein structure (Levine, 1997) . Functional analysis of mutant proteins has shown that the common biological eect of the mutations observed in human tumours is the inactivation of p53 as a transcription factor. These data have mostly been obtained using transcriptional indicator plasmids containing the ®rst identi®ed p53 binding site, the RGC sequence, located near a putative replication origin of the ribosomal gene cluster (Kern et al., 1991) . Although binding to RGC has been used to discriminate mutant from wild-type p53 (Scharer and Iggo, 1992; Kern et al., 1992; Frebourg et al., 1992; Chen et al., 1993; Ishioka et al., 1993; Ory et al., 1994; Pietenpol et al., 1994; Flaman et al., 1995) , this binding probably has no relevance in vivo.
One p53 mutant (175P) has recently been shown to retain the ability to activate p21-mediated G1 arrest, but not bax-mediated apoptosis Rowan et al., 1996) . The likely basis for this dierence is that this type of mutant has a modestly reduced anity for DNA, allowing it to bind to p21 but not bax or bax-like sites in vivo. Since p21 has been shown to protect against cell killing by chemotherapeutic drugs in some settings (Waldman et al., 1997) , proper biological classi®cation of p53 mutants may have important clinical implications. We have therefore developed simple yeast functional assays which can identify mutants competent for transactivation of p21 but not bax promoters.
p21 and bax reporter plasmids, containing the ADE2 open reading frame controlled by a p53-responsive element, were integrated at the URA3 locus of the ade2-yeast strain, YPH500 (Sikorski and Hieter, 1988) . The p21 reporter contains one copy of a 20 bp sequence found 2.4 kb upstream of the p21 promoter (GAACATGTCCCAACATGTTG, El-Deiry et al., 1993) . The bax reporter contains a 39 bp sequence found 486 ± 448 bp upstream of the bax promoter (TCACAAGTTAGAGACAAGCCTGGG-CGTGGGCTATATTG, Miyashita et al., 1995) . The bax 4 plasmid contains four copies of this site. The resulting strains, YPH-p21, YPH-bax and YPH-bax 4 , were red when grown on media containing limiting adenine. Activation of the reporters by wild-type p53 cDNA cloned in vivo by homogous recombination, results in white colonies ( Figure 1 ). We analysed the 173L and 175P whose eect on p21 and bax transactivation had previously been characterized in mammalian cells . As expected, the 173L mutant failed to activate both the p21 and bax reporter systems, and the 175P mutant selectively failed to activate the bax reporter plasmid (Figure 1 ). We analysed 51 mutations located within the DNAbinding domain and documented in human tumours. We observed, using the YPH-p21 and YPH-bax strains, two patterns (Table 1) : most mutants (42) were unable to activate either reporter. Like the 175P mutant, eight other mutants (120R, 175C, 175L, 175S, 181L, 181H, 254F, 283H) were able to activate the p21 reporter, but not the bax reporter (Table 1, Figure 1 ). Increasing the number of binding sites for a transcription factor commonly leads to an increase in transactivation, and this was observed in the YPH-bax 4 strain with the 175C, 175L, 175S, and 181L mutants (Table 1) .
To con®rm that the changes in colony colour re¯ect dierences in DNA binding, selected mutants expressed in yeast were tested in bandshift assays (Figure 2 ). Wild-type p53 shifted both the p21 and bax probes, and the complex was shown to be p53-speci®c (Figure 2a, b) by supershifting with anti-p53 antibody (PAb1801) but not irrelevant antibody (PAb204). Competition of the p53-p21 site complex with cold p21 probe, but not with cold bax probe, showed that p53 has a higher anity for the p21 site than for the bax site (Figure 2c ). With the p21 probe, the 272L and 277Y showed a reduced binding whereas 181L and 283H mutants gave binding comparable to wild-type p53 (Figure 2a ). With the bax probe, the 181L, 272L and 283H mutants all showed reduced binding and 277Y did not bind at all (Figure 2b ).
The common biological eect of tumour-derived p53 mutations which emerges from this study is a defect in transactivation of the bax reporter. This probably re¯ects the lower anity even of wild-type p53 protein for the bax site than the p21 site (Friedlander et al., 1996) . The p21 site (GAACATGTCC/CAA-G) contains two mismatches with the p53 consensus. In contrast, the bax site (TCACAAGTTA/G/AGA-CAAGCCT), contains three mismatches. Since p53 only makes phosphate backbone contacts with the ®rst and last residues in the decamer, variation at these positions is well tolerated. The third mismatch in the bax sequence aects a major groove base contact with 120K, and must signi®cantly reduce anity. Other dierences are that the p21 site contains AT in the centre of each decamer, versus AA in the bax site, and the two decamers are not immediately adjacent in the bax site: both dierences will further accentuate the dierences in anity for the two sites (Thukral et al., 1995) .
This study provides no evidence that the dierence in biological activity of the 173L, 175P and 181L mutants in mammalian cells Figure 1 Analysis of p53 mutants in YPH-bax (left) and YPHp21 (right) strains. Wild-type or de®ned mutant p53 cDNAs cloned in plasmids were PCR-ampli®ed, as previously described (Flaman et al., 1995) . Strains were cotransformed with unpuri®ed PCR product, pSS16 expression vector linearised by HindIII and StuI and carrier DNA using the lithium acetate procedure, as previously described (Flaman et al., 1995) , then plated on synthetic minimal medium minus leucine plus 2.5 ± 5 mg/ml adenine and incubated for 2 ± 3 days at 358C. For each mutant, one colony was replicated on selective medium and incubated at 358C for 3 days + + + + a In each strain, the activity of the p53 mutants was determined by the color of more than 200 colonies. +, positive (white colonies); 7, negative (red colonies). Mutations with dierential eects on bax and p21 transactivation are presented at the bottom of the table re¯ects a dierence in sequence speci®city per se. In fact, we did observe a dierence in speci®city with a mutant generated by experimental mutagenesis, 121F (Freeman et al., 1994) , which gave red colonies with p21 and white colonies with bax (data not shown). For four mutations, we observed a discrepancy between the results obtained in the YPH-bax and YPH-bax 4 strains ( Table 1 ), suggesting that the corresponding mutations have a subtle eect on bax transactivation and that there is a gradient in the eect of mutations on the transcriptional activity of p53. The 181L mutant was previously shown to transactivate a bax reporter plasmid in Saos-2 cells but we did not observe this transactivation in yeast. These con¯icting data might be explained by the dierence in the level of p53 expression between mammalian and yeast cells. The subtle eect of the 181L mutation, that we observed in yeast, is in agreement with the reduction of the apoptotic activity of the protein documented in Saos-2 cells .
Bax has tumour suppressor activity (Yin et al., 1997 ) and somatic bax mutations, resulting from DNA polymerase slippage, have been identi®ed in mismatch repair-de®cient tumours retaining wild-type p53 genes (Rampino et al., 1997) , which suggests the importance of bax inactivation in malignant transformation. However, bax-null mice retain p53-dependent apoptosis, and extensive screens for p53 target genes have shown apoptosis induction without bax induction (Polyak et al., 1997) . These results could suggest that p53-mediated apoptosis depends on other target genes and it will be important to determine if p53 has a high anity for these other targets. The defective transactivation, that we detected with the bax reporter strain, should probably be taken to re¯ect a defect in p53-dependent transactivation of low anity targets in Figure 2 Bandshift assays using p21 (a and c) or bax (b) probes and protein extracts containing wild-type or mutant p53. PAb1801 (anti-p53 monoclonal antibody) but not PAb204 (anti-SV40 T antigen monoclonal antibody) supershift the speci®c p53-DNA complex. NS, nonspeci®c complex. In c, binding of wild type and 283H mutant p53 to the p21 probe was competed by a 50-fold excess of cold p21, bax or irrelevant control probe. Bandshift assays were performed as described by Freeman et al. (1994) . The bandshift probes were derived from the ADE2 reporter plasmids by PCR ampli®cation of a 77 bp fragment containing single copies of the bax and p21 oligonucleotides. To avoid variable latency (Hupp et al., 1992) general rather than exclusively a defect in bax induction. This view is supported by the ®nding that a reporter with a single RGC site driving ADE2 expression behaves similarly to the bax reporter (data not shown).
Other mechanisms than transcriptional activity, such as protein-protein interactions, might be involved in p53 function (Levine, 1997) . Although the strains we describe test only the transcriptional competence of p53, they may have important clinical applications. p21-null cell lines are more sensitive to radiotherapy and chemotherapy than their wild-type counterparts (Waldman et al., 1997) , suggesting that by arresting the cell cycle, p21 may protect against apoptosis. Thus tumours containing p53 mutants capable of activating p21 induction may respond dierently to treatment than tumours containing conventional p53 mutants, and the p21 reporter strain could be used to identify these tumours. Basically charged peptides derived from the p53 carboxy-terminus can induce apoptosis in cell lines containing p53 mutants with structurally intact DNA binding domains (Selivanova et al., 1997) , and the peptido-mimetic drugs might one day be developed which can induce the same response in vivo. Therefore, in the short term, the strains may be useful for studies on p53 biology and tumour prognosis. In the long term, the reporter strains could provide simple means to select tumours with relatively mild-p53 defects which are more likely to respond to peptido-mimetic therapy.
